Using MRI and tumor genetics to guide treatment for small kidney tumors
Official title: Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform
Run by IRCCS San Raffaele · NCT06868927 · Data updated 2026-11-12
This project will test whether combining MRI images with tumor biopsy genetics and tissue mapping can help guide treatment choices for adults with small (≤4 cm) kidney tumors who are having surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milan, Italia) |
| Status | Recruiting |
| Started | September 26, 2025 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | March 17, 2026 |
| Trial ID | NCT06868927 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with a renal mass up to 4 cm who are scheduled for surgery, can undergo MRI, and provide informed consent are the intended participants.
✕Probably not a fit
Patients who cannot have an MRI, who have larger or metastatic tumors, or who are not surgical candidates are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational translational project integrates standard histology, immunohistochemistry, spatial transcriptomics, and genomic profiling of surgical tumor samples with MRI-based radiomics to build a radiogenomics decision platform. Adults with renal masses up to 4 cm who are candidates for renal surgery and can undergo MRI will be enrolled. Imaging and molecular data will be correlated to search for markers that predict response to systemic therapies or ablative treatments. The aim is to link noninvasive imaging features to underlying tumor biology to improve future treatment decisions.
Why it matters
Potential benefit: If successful, this approach could help doctors choose more precise treatments for small kidney tumors using MRI plus molecular biopsy data, potentially avoiding unnecessary therapies.
How similar studies have gone: Similar radiogenomics and spatial transcriptomics approaches have shown promising early results in small series but remain exploratory and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presence of a renal mass up to 4 cm * Adult \> 18 years * Candidate to renal surgery * Informed consent signed Exclusion Criteria: * Contraindication for MRI
Where it's running
-
IRCCS Ospedale San Raffaele
Milan, Italia, Italy Recruiting
Study contacts
- Study coordinator: Umberto Capitanio
- Email: caitanio.umberto@hsr.it
- Phone: 3492503788
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
RUS NE surgical navigation for robot-assisted partial nephrectomy
This trial will test whether the RUS NE surgical navigation software helps surgeons perform robot-assisted partial nephrectomy faster for adults with renal tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.